The FDA cleared an investigational new drug application for CYNK-101, a natural killer cell therapy for the treatment of patients with advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.
The clearance includes use of the investigational cell therapy in combination with chemotherapy, trastuzumab (Herceptin, Genentech) and pembrolizumab (Keytruda, Merck).